Anuh Pharma Limited
Anuh Pharma Limited (ANUHPHR) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
anuhpharma.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 198 Cr | 186 Cr | 186 Cr | 197 Cr |
| Operating expenses (approx.) | 179 Cr | 176 Cr | 174 Cr | 180 Cr |
| EBITDA | 19 Cr | 10 Cr | 12 Cr | 17 Cr |
| OPM % | 9.4% | 5.5% | 6.4% | 8.5% |
| Other income | 1 Cr | 3 Cr | 0.98 Cr | 4 Cr |
| Interest | 0.03 Cr | 0.21 Cr | 0.08 Cr | 0.08 Cr |
| Depreciation | 3 Cr | 3 Cr | 3 Cr | 3 Cr |
| Profit before tax | 17 Cr | 11 Cr | 10 Cr | 18 Cr |
| Tax % | 27.9% | 24.2% | 23.3% | 24.6% |
| Net profit | 12 Cr | 8 Cr | 8 Cr | 13 Cr |
| EPS (₹) | ₹2.49 | ₹1.66 | ₹0.76 | ₹1.34 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 662 Cr | Sign in for TTM |
| Operating expenses (approx.) | 601 Cr | Sign in for TTM |
| EBITDA | 61 Cr | Sign in for TTM |
| OPM % | 9.2% | Sign in for TTM |
| Other income | 9 Cr | Sign in for TTM |
| Interest | 0.62 Cr | Sign in for TTM |
| Depreciation | 9 Cr | Sign in for TTM |
| Profit before tax | 61 Cr | Sign in for TTM |
| Tax % | 22.4% | Sign in for TTM |
| Net profit | 47 Cr | Sign in for TTM |
| EPS (₹) | ₹9.45 | Sign in for TTM |
| Dividend payout % | 26.4% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 25 Cr |
| Reserves | 301 Cr |
| Borrowings | 10 Cr |
| Other liabilities | 170 Cr |
| Total liabilities | 507 Cr |
| Fixed assets (net) | 50 Cr |
| CWIP | 0.27 Cr |
| Investments | 106 Cr |
| Loans & advances | 0.55 Cr |
| Inventories | 74 Cr |
| Trade receivables | 216 Cr |
| Cash & bank | 20 Cr |
| Other assets | 41 Cr |
| Total assets | 507 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 37 Cr |
| Cash from investing | -20 Cr |
| Cash from financing | -5 Cr |
| Net cash flow | 12 Cr |
| Free cash flow (OCF − Capex) | 17 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 18.3% |
| ROE % | 14.5% |
| Debtor days | 119 |
| Inventory days | 59 |
| Days payable | 123 |
| Cash conversion cycle | 54 |
| Debt / equity | 0.03 |
| Current ratio | 2.11 |
| Net debt / EBITDA | -0.15 |
Compare with peers
Loading peers…